Atheronova Inc (AHRO) 0.0235 $AHRO
AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection
PR Newswire - Tue Mar 03, 7:45AM CST
AtheroNova Inc. (OTCQB: AHRO) today announced that the Company and its subsidiary, AtheroNova Operations, Inc., filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court, Central District of California, Santa Ana division (the "Bankruptcy Court"
on March 2, 2015. The Company's Chapter 11 cases are expected to be jointly administered.
MicroCap Outlook for Thursday February 19, 2015
ACCESSWIRE - Thu Feb 19, 8:20AM CST
CORAL GABLES, FL / ACCESSWIRE / February 19, 2015 / Big returns often come in small packages so they say. Since the bull market started in March 2009, the Russell 2000 index is up 215% compared to a 180% gain in the S&P 500. In addition to this, statistics from Vanguard show that between 1927 and 2012, small-cap stocks produced average annual returns of 12.9% vs. a 9.9% gain for their larger counterparts. Small and micro-cap stocks have gotten an unfair reputation as being too risky or volatile for many investors. The truth is, however, that many who write off these asset classes are missing out on solid earnings potential from some of fastest growing and innovative companies in the market.
AtheroNova awarded Notice of Issuance of third US patent
M2 - Mon Feb 16, 5:49AM CST
AtheroNova (Other OTC:AHRO) reported on Friday that it has received a Notice of Issuance of Patent No. 8952067 titled 'Subcutaneous Fat Reduction' from the US Patent and Trade Office, with an expiration date of 20 June 2032.
AtheroNova Receives Notice of Debt Acceleration
PR Newswire - Fri Feb 13, 2:23PM CST
AtheroNova Inc. (OTCQB: AHRO) today announced that it filed a Current Report on Form 8-K disclosing that on February 12, 2015 it received a notice of acceleration from Europa International, Inc., the holder of a 2.5% Senior Secured Convertible Note ("2.5% Note" issued by the Company in the principal amount of $427,500. The 2.5% Note was due and payable on November 12, 2014 and the holder was entitled to accelerate outstanding amounts under the 2.5% Note on November 26, 2014. While the Company attempted to negotiate an extension of the maturity date of the 2.5% Note, those negotiations were ultimately unsuccessful. The acceleration of the indebtedness under the 2.5% Note entitles the holder to receive 120% of the outstanding principal plus accrued and unpaid interest and other costs and expenses arising thereunder. The 2.5% Note also began to accrue interest at 12% per annum from November 26, 2014.
AtheroNova Receives Notice of Issuance of Its 3rd US Patent
PR Newswire - Fri Feb 13, 7:10AM CST
AtheroNova Inc. (OTCQB: AHRO) today announced that it has received a Notice of Issuance of Patent No. 8952067 titled "Subcutaneous Fat Reduction" by the United States Patent and Trade Office with an expiration date of June 20, 2032.
AtheroNova concludes USD3m in public offering
M2 - Mon Nov 03, 3:39AM CST
Biotech company AtheroNova (Other OTC:AHRO) disclosed on Friday the completion of its follow-on public offering of 4,000,000 shares of common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock.
AtheroNova Prices Public Offering of Common Stock and Warrants
PR Newswire - Tue Oct 28, 4:58PM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock and warrants to purchase up to an aggregate of 5,000,000 shares of its common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock. The securities are offered at a price to the public of $0.75 per share of common stock and $0.01 per warrant. The warrants will have an exercise price of $4.00 per share, subject to adjustment, and are exercisable immediately and will expire 5 (five) years from the date of issuance. The gross proceeds from this offering to AtheroNova are expected to be $3,050,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by AtheroNova. AtheroNova has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock and/or warrants to purchase up to an aggregate of 750,000 shares of its common stock. The offering is expected to close on or about October 31, 2014, subject to customary closing conditions. AtheroNova intends to use the net proceeds from the offering, as well as its other existing capital resources, for general corporate purposes, including working capital, operating expenses and capital expenditures.
AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection
PR Newswire - Tue Mar 03, 7:45AM CST
AtheroNova Inc. (OTCQB: AHRO) today announced that the Company and its subsidiary, AtheroNova Operations, Inc., filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court, Central District of California, Santa Ana division (the "Bankruptcy Court"
on March 2, 2015. The Company's Chapter 11 cases are expected to be jointly administered. MicroCap Outlook for Thursday February 19, 2015
ACCESSWIRE - Thu Feb 19, 8:20AM CST
CORAL GABLES, FL / ACCESSWIRE / February 19, 2015 / Big returns often come in small packages so they say. Since the bull market started in March 2009, the Russell 2000 index is up 215% compared to a 180% gain in the S&P 500. In addition to this, statistics from Vanguard show that between 1927 and 2012, small-cap stocks produced average annual returns of 12.9% vs. a 9.9% gain for their larger counterparts. Small and micro-cap stocks have gotten an unfair reputation as being too risky or volatile for many investors. The truth is, however, that many who write off these asset classes are missing out on solid earnings potential from some of fastest growing and innovative companies in the market.
AtheroNova awarded Notice of Issuance of third US patent
M2 - Mon Feb 16, 5:49AM CST
AtheroNova (Other OTC:AHRO) reported on Friday that it has received a Notice of Issuance of Patent No. 8952067 titled 'Subcutaneous Fat Reduction' from the US Patent and Trade Office, with an expiration date of 20 June 2032.
AtheroNova Receives Notice of Debt Acceleration
PR Newswire - Fri Feb 13, 2:23PM CST
AtheroNova Inc. (OTCQB: AHRO) today announced that it filed a Current Report on Form 8-K disclosing that on February 12, 2015 it received a notice of acceleration from Europa International, Inc., the holder of a 2.5% Senior Secured Convertible Note ("2.5% Note"
issued by the Company in the principal amount of $427,500. The 2.5% Note was due and payable on November 12, 2014 and the holder was entitled to accelerate outstanding amounts under the 2.5% Note on November 26, 2014. While the Company attempted to negotiate an extension of the maturity date of the 2.5% Note, those negotiations were ultimately unsuccessful. The acceleration of the indebtedness under the 2.5% Note entitles the holder to receive 120% of the outstanding principal plus accrued and unpaid interest and other costs and expenses arising thereunder. The 2.5% Note also began to accrue interest at 12% per annum from November 26, 2014. AtheroNova Receives Notice of Issuance of Its 3rd US Patent
PR Newswire - Fri Feb 13, 7:10AM CST
AtheroNova Inc. (OTCQB: AHRO) today announced that it has received a Notice of Issuance of Patent No. 8952067 titled "Subcutaneous Fat Reduction" by the United States Patent and Trade Office with an expiration date of June 20, 2032.
AtheroNova concludes USD3m in public offering
M2 - Mon Nov 03, 3:39AM CST
Biotech company AtheroNova (Other OTC:AHRO) disclosed on Friday the completion of its follow-on public offering of 4,000,000 shares of common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock.
AtheroNova Prices Public Offering of Common Stock and Warrants
PR Newswire - Tue Oct 28, 4:58PM CDT
AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock and warrants to purchase up to an aggregate of 5,000,000 shares of its common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock. The securities are offered at a price to the public of $0.75 per share of common stock and $0.01 per warrant. The warrants will have an exercise price of $4.00 per share, subject to adjustment, and are exercisable immediately and will expire 5 (five) years from the date of issuance. The gross proceeds from this offering to AtheroNova are expected to be $3,050,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by AtheroNova. AtheroNova has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock and/or warrants to purchase up to an aggregate of 750,000 shares of its common stock. The offering is expected to close on or about October 31, 2014, subject to customary closing conditions. AtheroNova intends to use the net proceeds from the offering, as well as its other existing capital resources, for general corporate purposes, including working capital, operating expenses and capital expenditures.
